Literature DB >> 19559447

Expression levels of cyclin G2, but not cyclin E, correlate with gastric cancer progression.

Min-Gew Choi1, Jae Hyung Noh, Ji Yeong An, Seong Kweon Hong, Sung Bae Park, Yong Hae Baik, Kyoung-Mee Kim, Tae Sung Sohn, Sung Kim.   

Abstract

PURPOSE: Cyclin G2 and cyclin E are important cell-cycle regulators in various cancer tissues. However, little is known about cyclin G2 expression in human gastric cancer tissues, and the role of cyclin E is quite controversial. This study evaluated their clinical significance in gastric cancer tissues.
MATERIALS AND METHODS: Immunohistochemical staining using the tissue array method was performed on 166 human gastric carcinomas. The clinicopathological features and prognostic significance were analyzed.
RESULTS: Cyclin G2 and cyclin E expressions were positive in 110 (66.3%) and 77 (46.4%) human gastric cancer tissues, respectively. The incidence of cyclin G2 positivity was lower in females and in cancers with the undifferentiated type of histology. Moreover, cyclin G2 expression was inversely correlated with the more advanced stages (P < 0.05), the presence of lymph-node metastasis (P < 0.05), and the presence of perineural invasion (P < 0.05). However, no significant correlation was observed between the expression of cyclin E and all of the clinicopathological factors examined. Cyclin G2 expression was associated with a better overall survival (OS; 5-y OS, 50.6% for cyclin G2-positive versus 35.0% for cyclin G2-negative; P < 0.05). However, multivariate analysis revealed lymph-node metastasis, distant metastasis, and lymphatic invasion to be independent prognostic factors but not cyclin G2 expression.
CONCLUSION: Our study could not demonstrate any significant relationship between cyclin E expression and the clinicopathological variables. However, cyclin G2 appears to be a negative cell-cycle regulator in gastric cancer, and its expression seems to be inversely related to gastric cancer progression.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19559447     DOI: 10.1016/j.jss.2008.06.020

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  17 in total

1.  Cyclin G2: A novel independent prognostic marker in pancreatic cancer.

Authors:  Shinichiro Hasegawa; Hiroaki Nagano; Masamitsu Konno; Hidetoshi Eguchi; Akira Tomokuni; Yoshito Tomimaru; Hiroshi Wada; Naoki Hama; Koichi Kawamoto; Shogo Kobayashi; Shigeru Marubashi; Naohiro Nishida; Jun Koseki; Noriko Gotoh; Shouichi Ohno; Norikazu Yabuta; Hiroshi Nojima; Masaki Mori; Yuichiro Doki; Hideshi Ishii
Journal:  Oncol Lett       Date:  2015-09-02       Impact factor: 2.967

2.  Gut microbiome disruption altered the biotransformation and liver toxicity of arsenic in mice.

Authors:  Liang Chi; Jingchuan Xue; Pengcheng Tu; Yunjia Lai; Hongyu Ru; Kun Lu
Journal:  Arch Toxicol       Date:  2018-10-24       Impact factor: 5.153

3.  Prediction of human targets for viral-encoded microRNAs by thermodynamics and empirical constraints.

Authors:  Alessandro Laganà; Stefano Forte; Francesco Russo; Rosalba Giugno; Alfredo Pulvirenti; Alfredo Ferro
Journal:  J RNAi Gene Silencing       Date:  2010-05-24

4.  Changes in the expression of cyclin G2 in esophageal cancer cell and its significance.

Authors:  J Q Chen; C J Liu; H X Wen; C L Shi; H S Zhang; M Li; G G Sun
Journal:  Tumour Biol       Date:  2013-12-03

5.  Effect of cyclin G2 on proliferative ability of prostate cancer PC-3 cell.

Authors:  D W Cui; Y J Cheng; S W Jing; G G Sun
Journal:  Tumour Biol       Date:  2013-11-29

6.  CCNG2 expression is downregulated in colorectal carcinoma and its clinical significance.

Authors:  G G Sun; J Zhang; W N Hu
Journal:  Tumour Biol       Date:  2013-12-03

7.  Decreased expression of CCNG2 is significantly linked to the malignant transformation of gastric carcinoma.

Authors:  G G Sun; W N Hu; D W Cui; J Zhang
Journal:  Tumour Biol       Date:  2013-11-19

8.  Research and clinical applications of molecular biomarkers in gastrointestinal carcinoma (Review).

Authors:  Feng Jiao; Ziliang Jin; Lei Wang; Liwei Wang
Journal:  Biomed Rep       Date:  2013-08-20

9.  Change in expression of cyclin G2 in kidney cancer cell and its significance.

Authors:  D W Cui; G G Sun; Y J Cheng
Journal:  Tumour Biol       Date:  2013-11-23

10.  Cyclin G2 suppresses estrogen-mediated osteogenesis through inhibition of Wnt/β-catenin signaling.

Authors:  Jinlan Gao; Qi Liu; Xing Liu; Chunyan Ji; Shengqiang Qu; Shusen Wang; Yang Luo
Journal:  PLoS One       Date:  2014-03-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.